摘要
目的联合检测血清和胸水中细胞角蛋白19片段(CYFRA21-1)和CEA含量,旨在探讨其对良、恶性胸水的鉴别诊断意义。方法用免疫放射法(IRMA)检测血清及胸水CYFRA21-1,并用放射免疫法(RIA)检测CEA水平。结果非小细胞肺癌(NSCLC)组胸水CYFRA21-1较结核组及小细胞肺癌(SCLC)组明显增高(P<0.01);NSCLC组胸水CYFRA21-1较血清CYFRA21-1亦明显升高(P<0.01);结核组CEA胸水/血清值(CEAp/s)较肺癌组明显低(P<0.01);联合检测胸水CYFRA21-1及CEAp/s对肺癌诊断的敏感性为100%,特异性为76.8%,准确性为88.4%。结论联合检测胸水和血清CYFRA21-1及CEAp/s对良、恶性胸水的鉴别诊断有一定价值。
Objective To measure CYFRA 21-1 and CEA levels in serum and pleural fl uid and investigate the roles in differentiation diagnosis of benig n and malignant pleural fluid.Methods To measure CYFRA 21-1 levels in serum and pleural fluid by RIA.Results CYFRA 21-1 levels of non-small lung cancer(NSCLC)group were higher than those of tuberculosis group and small cell lung cancer(SCLC)group in pleural fluid(P<0.01).CYFRA 21-1 level of pleural fluid was higher than that of serum in NSCLC group.The ration of pl eural fluid to serum for CEA(CEA p /s)in tuberculosis group was lower than that of in lung cancer group(P<0.01).If CYFRA 21-1 levels and CEA p /s in pleural fluid we re measured simultaneously rate were 100%,the specificity rate was 76.8%,the a ccuracy rate was 88.4%.Conclusions It had potential value to measure CYFRA 21-1 levels and CEA p /s simultaneously for diffe rentiation diagnosis of benign and malignant pleural fluid.[
出处
《中国航天医药杂志》
2002年第4期32-34,共3页
Medical Journal of CASE
